Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
Market Analysis and Insights: Global and United States Amyotrophic Lateral Sclerosis (ALS) Market
This report focuses on global and United States Amyotrophic Lateral Sclerosis (ALS) market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Amyotrophic Lateral Sclerosis (ALS) market size is estimated to be worth US$ 489.8 million in 2022 and is forecast to a readjusted size of US$ 1243.5 million by 2028 with a CAGR of 16.8% during the review period. Fully considering the economic change by this health crisis, by Type, Riluzole accounting for % of the Amyotrophic Lateral Sclerosis (ALS) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Hospital was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
In United States the Amyotrophic Lateral Sclerosis (ALS) market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period.
Global Amyotrophic Lateral Sclerosis (ALS) Scope and Market Size
Amyotrophic Lateral Sclerosis (ALS) market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Amyotrophic Lateral Sclerosis (ALS) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Amyotrophic Lateral Sclerosis (ALS) market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Riluzole
Edaravone (Radicava)
Other
Segment by Application
Hospital
Drugs Store
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma